Daunorubicin

Latest News for: daunorubicin

Edit

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos� (daunorubicin and cytarabine) for the ...

The Daily Times 31 Mar 2021

Food and Drug Administration (FDA) approved a revised ...

Edit

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the ...

Odessa American 31 Mar 2021

Food and Drug Administration (FDA) approved a revised label for Vyxeos® (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older.

Edit

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients (Jazz Pharmaceuticals plc)

Public Technologies 31 Mar 2021

Edit

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

PR Newswire 30 Mar 2021

Edit

Jazz Pharmaceuticals Announces the Poster Publication of Vyxeos® Liposomal (daunorubicin and cytarabine) Long-Term Phase 3 Data for Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukaemia at EHA Annual Congress

Pharmiweb 12 Jun 2020

The reported adverse reactions with CPX-351 were generally consistent with the known safety profile of cytarabine and daunorubicin therapy in the Phase 3 study.1 ... In the US, Vyxeos® (daunorubicin and cytarabine) is a liposomal formulation of a fixed combination of ...

Edit

Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019

PR Newswire 14 Jun 2019

... and daunorubicin in patients with newly diagnosed acute myeloid leukemia (AML) ... Preliminary data from the study indicated that alvocidib in combination with cytarabine and daunorubicin has shown clinical activity with acceptable safety in patients with newly diagnosed AML.